Navigation Links
Weikang Bio-technology Group, Inc. Completes HQ Relocation After Purchasing Building for $14 Million and Answers Questions About its Third Quarter Financials
Date:12/28/2011

HARBIN, China, Dec. 28, 2011 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-technology Group, Inc. (the "Company," "Weikang" or WKBT.PK) today announced that the Company has completed moving all of its management departments into the building it purchased last quarter for $14 million. Located at No.365 Chengde Street in the Daowai District of Harbin, the hub of northeast China, Weikang previously rented two floors of the building.

Mr. Yin Wang, the Chairman and CEO of Weikang commented, "We are very glad that finally we have our own headquarters building, which can accommodate all of our departments, instead of having to rent different places for different departments."

On a conference call on December 15, 2011, Mr. Wang explained to investors about the WKBT HQ building and its purchase. "The building has ten floors with 7,000 square meters (approximately 70,000 square feet) and I believe it will improve our management efficiency. Although the $14 million price tag of the building is a big number, it already came down from its peak asking price by its previous owner, which is a local credit union. We believe it is necessary to include this building at this moment as part of our business expansion plan for the next few years."

Mr. Wang also answered some additional investor questions regarding WKBT's third quarter financial statements from the list below:

Question:

Why did Net Sales increase 11% from the prior year yet Accounts Receivable increased 10 times from $650,000 to $6.5 million?

Answer:

"The market for our products has been affected by the slowing down of the economy in China in the recent months. To cope with that, we extended credit terms to some large customers from 30 days to 60 days. As result, the AR increased to $6.5 million, the collection of which has been very good with no delays. Despite the increase in AR, percentage-wise, the amount is still under control," said Chairman Wang.

Question:

Advances to Suppliers and Other Receivable increased more than 20 times from $241,000 to $5.2 million. Please explain.

Answer:

"The raw material price has been increased significantly during the last few months affected by the inflation of the whole economy in China. We believed the prices of raw materials would continue to increase. Therefore, we entered a large contract with a large supplier to lock down the price of raw material, for which we paid about $5 million as a down payment.  We believe this is necessary to control the cost," Mr Wang said.

Question:

Income before tax was $8.4 million last year, but only $3.5 million this year. Yet, the income tax expense increased despite an almost 60% decline in taxable income. Please explain.

Answer:

"This is because there was about $4.3 million in one-time, non-cash expenses in the G&A Expenses in the last quarter, which resulted from stock issuance to some consultants and a consulting firm, which we believe are necessary and critical for our long term business development. So the income before tax was $3.5 million down from $8.4 million but since the non-cash expenses was not deductible from the taxable income for tax purposes, the income tax expense still increased along with our revenue increase," clarified Mr. Wang.

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd. For more information, please visit http://www.weikangbio.com.

Contact:

Yue Kang (Venus):
+86 4-518-835-5530
+86 15846588061
Email: weikangbio@yahoo.com

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.


'/>"/>
SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weikang Bio-Technology to Present at Rodman & Renshaw Annual China Investment Conference
2. Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
3. Weikang Bio-Technology Expects to Report Fiscal 2010 Revenue of $77.8 Million and Net Income of $31.2 Million or $1.04 Earnings per Share
4. Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
5. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
6. Weikang Bio-Technology Announces Filing for NASDAQ Listing
7. Weikang Bio-Technology Reports First Quarter 2010 Financial Results
8. Unity Management Group, Inc. Announces Its Initial Sale of the PZ UNO Tablet Press to a Major Pharmaceutical Company for $500,000
9. Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical Indias Largest Pharmaceutical Companies for $105,000
10. Global Pharm Holdings Group, Inc. Announces Third Quarter 2011 Financial Results
11. Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Ahead of today,s trading session, Stock-Callers.com draws investors, ... at the close: Kite Pharma Inc. (NASDAQ: KITE ), ... and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). According to ... Friday, January 20 th , 2017, down on the day by ... stocks now at: ...
(Date:1/23/2017)... 2017 Longer life expectancy and rising healthcare expenditure ... for medical device technologies. BCC Research reveals in its new ... region, should see strong growth due to rising government healthcare ... Continue Reading ... ...
(Date:1/23/2017)... -- ResMed (NYSE: RMD ), BMC (Peking, ... Winter Haven, Florida ) gaben heute bekannt, dass ... globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt haben. BMC und ... im Tausch gegen Lizenzgebühren an ResMed gestattet, und ResMed ... in Florida anhängige Rechtsverfahren zwischen ...
Breaking Medicine Technology:
(Date:1/23/2017)... Pass, OR (PRWEB) , ... January 23, 2017 , ... ... took to the air to educate listeners about the benefits of making new water ... the U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... earned organic certification under the USDA National Organic Program (NOP) for its Portland ... we have established organic production and handling systems to complement our current rigorous ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... ... , ... Valentine’s Day is a time when many people celebrate romance and love by giving ... looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s ... spend $200 and get $50 free. , “A lot of people just buy the ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company ... ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with ... of its beauty and wellness products. At this trade show, the company had the ...
Breaking Medicine News(10 mins):